SCHEMBL23218189

SCHEMBL23218189

CCCc1oc2ccc(Br)cc2c1CO

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.43
MAPT P10636 5/20 0.42
LMNA P02545 3/20 0.41
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.41
KCNH2 Q12809 1/20 0.40
CA12 O43570 3/20 0.39
CA9 Q16790 3/20 0.39
CASP6 P55212 1/20 0.37
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
POLB P06746 1/20 0.36
KMT2A Q03164 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
TSHR P16473 1/20 0.35
ESR1 P03372 1/20 0.35
ESR2 Q92731 1/20 0.35
CHRNB2 P17787 1/20 0.35
CHRNA7 P36544 1/20 0.35
CHRNA4 P43681 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852875 1.00 PIM1 (0.43) PIM1MAPTLMNAALDH1A1HPGD
SCHEMBL29852587 0.88 PIM1 (0.45) PIM1MAPTLMNAALDH1A1HPGD
SCHEMBL23218086 0.88 PIM1 (0.45) PIM1MAPTLMNAALDH1A1HPGD
SCHEMBL23218325 0.84 MAPT (0.40) PIM1MAPTLMNAALDH1A1HPGD
SCHEMBL29591980 0.84 MAPT (0.40) PIM1MAPTLMNAALDH1A1HPGD
SCHEMBL10851844 0.81 ESR1 (0.43) PIM1MAPTLMNAALDH1A1HPGD
SCHEMBL7390540 0.79 MTNR1A (0.46) MAPTCA12CA9
SCHEMBL10857787 0.78 KCNH2 (0.50) PIM1MAPTLMNAALDH1A1HPGD
SCHEMBL23218435 0.78 KCNH2 (0.47) PIM1MAPTLMNAALDH1A1HPGD
SCHEMBL29853136 0.78 KCNH2 (0.47) PIM1MAPTLMNAALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
US-20160361275-A1 SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY ACADIA PHARMACEUTICALS INC. 2016-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160361275-A1 SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY SLC6A4, HTR4, GPR34 PIM1 3995/4885MAPT 234/4885LMNA 869/4885
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB PIM1 4538/4885MAPT 4793/4885LMNA 1698/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB PIM1 4497/4885MAPT 3561/4885LMNA 1844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.